Related Experiment Videos
Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis
A A Stenger1, P M Houtman, G A Bruyn
1Department of Rheumatology, Medical Centre Leeuwarden, The Netherlands.
Abstract:
Since 1983 there have been several reports on Pneumocystis carinii pneumonia (PCP), complicating low dose methotrexate (MTX) therapy for rheumatoid arthritis (RA). Two additional cases of this opportunistic infection are reported and a review of the literature on the complication is presented. It is concluded that PCP is a serious complication of low dose MTX therapy for RA and should always be ruled out when a patient presents with pulmonary symptoms. Several factors may play a role in the occurrence of this opportunistic infection, but the exact mechanism has not yet been elucidated.
Insights
Pneumocystis pneumonia (PCP) is a serious risk for rheumatoid arthritis patients on low-dose methotrexate (MTX) therapy. Always consider PCP in RA patients with lung symptoms during MTX treatment.
Area of Science:
- Rheumatology
- Infectious Diseases
- Pharmacology
Background:
- Low-dose methotrexate (MTX) is a common therapy for rheumatoid arthritis (RA).
- Pneumocystis pneumonia (PCP) is an opportunistic infection that can occur in immunocompromised individuals.
- Reports since 1983 have indicated a link between MTX therapy and PCP in RA patients.
Observation:
- Two new cases of PCP complicating MTX therapy for RA are presented.
- A review of existing literature on this complication was conducted.
Findings:
- PCP is a significant and serious complication associated with low-dose MTX treatment for RA.
- Pulmonary symptoms in RA patients on MTX therapy warrant prompt investigation for PCP.
Implications:
- Clinicians should maintain a high index of suspicion for PCP in RA patients experiencing respiratory issues while on MTX.
- Further research is needed to elucidate the exact mechanisms underlying MTX-associated PCP.
- Early diagnosis and management of PCP are crucial for improving outcomes in RA patients receiving MTX.